Observational Study of Abatacept (Orencia®) in Rheumatoid Arthritis
This study is looking at how the drug Abatacept (Orencia®) affects the immune system in people with Rheumatoid Arthritis (RA). Researchers want to understand how this medication changes certain immune cells (T cells and B cells) compared to people with RA taking other common treatments like methotrexate (MTX) or leflunomide (LEF), with or without TNF inhibitors, and also compared to healthy individuals. The goal is to learn more about what causes RA symptoms and to potentially predict which patients might respond best to these treatments. You may be eligible if you are 18 or older, have RA, and are either about to start Abatacept or are on stable RA medications. The study aims to enroll 72 participants.
- Study design
- This is an observational study comparing three groups of participants. It is not specified if it is blinded or randomized.
- What's involved
- Participants will be followed for 6 months. The specific procedures, visits, or tests are not detailed in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Changes in T cell and B cell repertoires will be measured between April 2024 and March 2025, indicating a follow-up period within that timeframe.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Analysis of T and B Cell Repertoire Changes in Response to Orencia® (Abatacept) in Rheumatoid Arthritis
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Louis Bridges, MD PhD · PRINCIPAL_INVESTIGATOR · Hospital for Special Surgery, New York
- Vivian P Bykerk, MD · PRINCIPAL_INVESTIGATOR · Hospital for Special Surgery, New York
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Change in clonotype diversity of T cell and B cell repertoiresApril 2024-March 2025
Investigators will compare the change in clonotype diversity of T cell and B cell repertoires in patients over 6 months by analyzing clonotype diversity of T cell and B cell repertoires at BL (pre-treatment), 3 months, and 6 months post treatment for each individual in each of the three groups (RA starting ABA; RA on stable MTX +/- TNFi.